First patient dosing with Pluvicto imminent in Korea
By Moon, sunh-ho | translator Kang, Shin-Kook
24.07.30 05:35:08
가나다라
0
Novartis tests the possibility of administering the drug at 11 hospitals in Korea within August
K-Bios also jump into competition to develop new radiopharmaceuticals despite equipment, spatial, and treatment limitations
Novartis Korea's prostate cancer drug Pluvicto, which has been in the spotlight since its approval by the Ministry of Food and Drug Safety, is gaining further attention as the company prepares to administer the first dose to patients in Korea.
Pluvicto is a blockbuster drug that generated more than KRW 1 trillion in global sales last year and is considered to have ushered in the era of so-called ‘radiopharmaceutical missiles’ in oncology.

# Unlike Bayer's Xofigo, which was licensed as a radioactive therapeutic agent in 2014 but was ignored by the market, Pluvicto opened a new era making noteworthy performance.
As a result, global pharmaceutical companies are rushing to de
Moon, sunh-ho(lib6983@dailypharm.com)
If you want to see the full article, please JOIN US (click)